Artificial Intelligence (AI) is entering a pivotal moment in healthcare. What began as a tool to assist providers with clinical documentation via ambient listening, is now evolving into something far ...

Taconic Biosciences, Inc., a global leader in genetically engineered rodent models (GEMs) and humanized immune system (HIS) mouse models, today announced the acquisition of TransCure bioServices SAS, ...

Understanding human gene function in living organisms has long been hampered by fundamental differences between species. Although mice share most protein-coding genes with humans, their regulatory ...

An enterprise employee is greeted by ‘Vikram’ as he loads an internal portal to create an IT ticket. Or a new hire’s guide in its HR portal is introduced as ‘Jenny.’ Names for virtual AI agents are ...

Forbes contributors publish independent expert analyses and insights. Davey Winder is a veteran cybersecurity writer, hacker and analyst. Newly published research from mobile threat intelligence ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Ellen Lee Ellen Lee is a writer focused on baby and kid gear. She has smashed ...

Jeff Somers is a freelancer who has been writing about writing, books, personal finance, and home maintenance since 2012. When not writing, Jeff spends his free time fixing up his old house. He has ...

In overseeing the expansion of the Islamic art galleries at the Metropolitan Museum, she countered hostile narratives about the Muslim world that arose after 9/11. By Jeré Longman Sheila R. Canby, a ...

BEIJING--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based ...

A fundamental challenge in preclinical research is accurately predicting human responses using conventional animal models. Traditional approaches often fail to adequately model human disease, creating ...

Efficacy and safety of dalpiciclib plus fulvestrant and pyrotinib in HR+, HER2-low advanced breast cancer following CDK4/6 inhibitor and aromatase inhibitor: A Bayesian optimal phase Ⅱ trial. This is ...